Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Histone Deacetylase Inhibitor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Histone Deacetylase Inhibitor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-000782-22 Sponsor Protocol Number: SAHA-Pilot-2016 Start Date*: 2017-01-03
    Sponsor Name:Medical University of Graz
    Full Title: A pilot study of peroral Vorinostat (Zolinza) in patients with refractory histone deacetylase-positive uterine sarcoma.
    Medical condition: Uterine sarcoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004480-21 Sponsor Protocol Number: DSC/07/2357/28 Start Date*: 2007-11-30
    Sponsor Name:ITALFARMACO
    Full Title: A phase IIA study of the histone-deacetylase inhibitor ITF2357 in patients with JAK-2 V617F positive chronic myeloproliferative diseases
    Medical condition: chronic myeloproliferative diseases
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028578 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001489-85 Sponsor Protocol Number: FRM-0334-002 Start Date*: 2015-02-23
    Sponsor Name:FORUM Pharmaceuticals Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects wit...
    Medical condition: Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) IT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002395-41 Sponsor Protocol Number: 309100 Start Date*: 2004-12-03
    Sponsor Name:Schering AG
    Full Title: Phase II study of MS-275, a histone deacetylase inhibitor, comparing 2 dosage schedules in patients with metastatic melanoma
    Medical condition: Metastatic malignant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004747-23 Sponsor Protocol Number: BPC01-001 Start Date*: 2014-01-17
    Sponsor Name:Bionor Pharma ASA
    Full Title: An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation using Romidepsin, on the Viral Reservoir in Virologic...
    Medical condition: HIV-infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003554-15 Sponsor Protocol Number: 18031977 Start Date*: 2006-11-09
    Sponsor Name:National Cancer Institute
    Full Title: The histone deacetylase inhibitor (HDAC) valproic acid as second line treatment for hormone refractory metastatic prostate cancer. A phase II. study.
    Medical condition: hormone refractory metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-009916-33 Sponsor Protocol Number: 00332/AMLSG14-09 Start Date*: 2011-05-13
    Sponsor Name:University Medical Center Freiburg
    Full Title: Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic...
    Medical condition: Patients older than 60 years with acute myeloid leukemia according to WHO (≥ 20 % blasts in the peripheral blood (pB) or bone marrow (BM)) not qualifying for, or not consenting to, standard remissi...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001770-42 Sponsor Protocol Number: 4745 Start Date*: 2018-10-24
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A multicenter phase II non-randomised trial assessing the efficacy of Domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colore...
    Medical condition: Advanced gastrooesophageal and colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042080 Stomach cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001076-18 Sponsor Protocol Number: 26481585LYM2001 Start Date*: 2011-09-20
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
    Medical condition: Stage Ib-IVa Cutaneous T-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10011677 Cutaneous T-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002744-27 Sponsor Protocol Number: CR01849 Start Date*: 2011-11-01
    Sponsor Name:Imperial College
    Full Title: Pharmacodynamic Studies of a Histone Deacetylase Inhibitor in FRDA
    Medical condition: Friedreich’s ataxia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-007139-26 Sponsor Protocol Number: S075LBH501 Start Date*: 2008-04-17
    Sponsor Name:SENDO TECH
    Full Title: A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC)
    Medical condition: SCLC patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041070 Small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007091-41 Sponsor Protocol Number: DSC/07/2357/31 Start Date*: 2008-01-19
    Sponsor Name:ITALFARMACO
    Full Title: Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin’s Lymphoma Patients
    Medical condition: Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020206 Hodgkin's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010982-22 Sponsor Protocol Number: DSC/08/2357/38 Start Date*: 2009-04-20
    Sponsor Name:ITALFARMACO
    Full Title: Phase II study of the histone-deacetylase inhibitor GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responder to hydroxyurea monotherapy
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10018847 Haematological disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005465-19 Sponsor Protocol Number: DSC/06/2357/21 Start Date*: 2007-02-09
    Sponsor Name:ITALFARMACO
    Full Title: Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects with chronic lynphocytic leukemia (CLL) refractory/relapsed after convention...
    Medical condition: Chronic lynphocytic leukemia (CLL) refractory/relapsed after conventional chemotherapy or relapsed after autologous bone marrow transplantation
    Disease: Version SOC Term Classification Code Term Level
    6.1 10008958 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002113-12 Sponsor Protocol Number: DSC/05/2357/17 Start Date*: 2006-09-19
    Sponsor Name:ITALFARMACO
    Full Title: Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects aged over 60 years with primary or secondary DLBCL refractory/ relapsed afte...
    Medical condition: Primary or secondary DLBCL refractory/relapsed after conventional chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003899 B-cell lymphoma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001084-56 Sponsor Protocol Number: DSC/04/2357/10 Start Date*: 2005-05-27
    Sponsor Name:ITALFARMACO
    Full Title: Phase II Multiple-Dose Clinical Trial of Oral ITF 2357 In Patients with Advanced Multiple Myeloma
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028228 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003336-72 Sponsor Protocol Number: 81413F Start Date*: 2013-10-30
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLGIA
    Full Title: A Phase IIb study of topic DAC-0060, a synthetic histone deacetylase inhibitor, plus Tazarotene in patients with cutaneous basal cell carcinoma (BCC)
    Medical condition: BASAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002281-23 Sponsor Protocol Number: Spon1345-14 Start Date*: 2016-06-13
    Sponsor Name:Cardiff University
    Full Title: A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML)
    Medical condition: Chronic myelomonocytic leukaemia (CMML)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000049-36 Sponsor Protocol Number: DSC/07/2357/26 Start Date*: 2007-05-07
    Sponsor Name:ITALFARMACO
    Full Title: Phase II study of the histone-deacetylase inhibitor ITF2357 in very high-risk relapsed/refractory Hodgkin's lymphoma patients
    Medical condition: Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020206 Hodgkin's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005537-11 Sponsor Protocol Number: NCT-2007-11-02-1004 Start Date*: 2011-07-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia
    Medical condition: Relapsed of progressive solid tumor, lymphoma, or leukemia in children and adolescents aage 3-18 years
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA